LOWELL, Mass., March 15, 2016 -- Rapid Micro Biosystems, a leading provider of automated, non-destructive, rapid microbial detection, is pleased to announce the addition of Natale (Nat) Ricciardi to its Board of Directors.
Mr. Ricciardi spent his entire 39-year career at Pfizer Inc, retiring in 2011. At retirement Nat held the positions of President, Pfizer Global Manufacturing and Senior Vice President, Pfizer Inc. In addition to his corporate leadership role, Nat was directly responsible for all of Pfizer’s internal and external supply organization – a global enterprise with as many as 38,000 employees and more than 100 manufacturing facilities supplying small and large molecule pharmaceuticals, vaccines, consumer, nutrition and animal health products. He played a leadership role in shaping a mission-driven and values-based culture as the company went through phases of growth, mergers and acquisitions and transformation. His relentless focus on Quality and Compliance became a competitive advantage. His passion for science and technology and for creating a culture of continuous improvement, as drivers of efficient and effective processes, were felt across Pfizer and delivered billions of dollars in cost savings as the business transformed.
“We are delighted to welcome Nat to the Board of Directors. He brings a wealth of experience in global manufacturing and quality operations in our target industries and will be a key advisor to Rapid Micro Biosystems as we continue to execute our vision of automating microbial quality control throughout the pharmaceutical, biotech, personal care and medical device industries,” said Robert Spignesi, Chief Executive Officer.
Mr. Ricciardi earned a degree in Chemical Engineering from the City College of New York (CCNY) and an M.B.A. in Finance and International Business from Fordham University. He serves on the Board of Directors of Dynavax Technologies, Inc., Asterias Biotherapeutics, Inc. and is on the Strategic Advisory Board of HealthCare Royalty Partners. He is currently a member of the Board of the 21st Century Foundation of CCNY.
“I am excited to join the Board of Directors of Rapid Micro Biosystems at a time when this company is making a significant impact in the pharmaceutical and biotechnology industries with new and innovative approaches to automated, rapid microbiological detection methods,” said Nat Ricciardi. “I look forward to contributing my experience in leading global manufacturing and quality operations to the Company’s success.”
About Rapid Micro Biosystems:
Rapid Micro Biosystems delivers the Growth Direct™ System, an automated, non-destructive rapid detection and enumeration technology based on the compendial method for microbial quality control in pharmaceutical manufacturing. The system automates and accelerates detection and enumeration in the areas of sterility testing, environmental monitoring, and bioburden testing, eliminating manual steps and analysis. The detection technology, first developed and patented by Dr. Don Straus, Ph.D., uses the natural auto-fluorescence of microbes and requires no reagents. For more information about Rapid Micro Biosystems visit www.rapidmicrobio.com
Contact: Eugenia Kendrick Rapid Micro Biosystems [email protected]


Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 



